Pneumonia, an inflammatory condition of the lung usually due to bacterial and/or viral infection, is the third leading cause of death worldwide and a major cause of morbidity and mortality in children, adults and the elderly.

    In Europe alone, pneumonia costs €10 billion each year and the effectiveness of treating bacterial pneumonia is declining due to antimicrobial resistance (AMR). It is crucial thus to develop new strategies to treat pneumonia, improve antibacterial treatment and reduce the huge socio-economic burden associated with AMR.

    Copyright © 2024 - FAIR - All Rights Reserved.